SION · NASDAQ · Biotechnology

Sionna Therapeutics (SION)

Develops NBD1-stabilizing and complementary CFTR modulators for cystic fibrosis.

$5.59
vs last close−0.43 (−7.23%)

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue00000000000
Gross profit00000000000
1313112818202224232932
Research & development101082514141516151922
33344677101011
Selling & marketing00000000000
General & administrative33044677101111
Other expenses000−10001−200
Operating income−13−13−11−28−18−20−22−24−24−30−32
11332344333
Interest income11322343333
Other non-operating income−1−1−3−3−2−3−4−4−6−3−3
Income before tax−12−12−9−25−16−16−18−20−20−27−30
Net income from continuing operations−12−12−9−25−16−16−18−20−20−27−30
Net income−12−12−9−25−16−16−18−20−20−27−30
EPS, basic−$0.27−$0.27−$0.19−$0.58−$0.36−$0.37−$0.41−$0.46−$0.46−$0.60−$0.66
EPS, diluted−$0.27−$0.27−$0.19−$0.58−$0.36−$0.37−$0.41−$0.46−$0.46−$0.60−$0.66
Weighted average shares, basic4444444444444444404545
Weighted average shares, diluted4444444444444444404545
EBITDA−12−11−8−25−16−16−18−20−17−27−30
Depreciation & amortization00000001100
EBIT−12−12−9−25−16−16−18−20−17−27−30